How does cosentyx consistently deliver results?
Cosentyx, a biologic treatment for psoriasis, is a fusion protein that targets interleukin-17A (IL-17A). Its consistent results can be attributed to the innovative mechanism of action (MOA) and the production process used by Novartis, the manufacturer of Cosentyx [1].
Stability and formulation of Cosentyx
Cosentyx is available as a pre-filled pen or syringe, designed for self-administration by patients. The prefilled pen contains a fixed dose of 100 mg/mL, ensuring accurate dosing with each injection [2]. The unique formulation of Cosentyx, using a proprietary recombinant technology, has been optimized to provide a high level of purity and stability, minimizing the risk of aggregation and degradation.
Preclinical and clinical evidence
Preclinical studies have demonstrated that Cosentyx effectively inhibits IL-17A, a key cytokine involved in the pathogenesis of psoriasis, thereby reducing inflammation and skin cell proliferation [3]. Clinical trials have consistently shown that Cosentyx significantly improves symptoms of psoriasis, achieving high response rates and maintaining efficacy over time [4].
Production process and quality control
Novartis employs a rigorous production process that ensures consistency across batches. The company adheres to Good Manufacturing Practices (GMPs) and conducts quality control at each stage of production, including cell banking, fermentation, and purification [5]. This comprehensive quality control process minimizes the risk of impurities or variability in the final product.
Patient outcomes and clinical trials
Real-world evidence from numerous clinical trials and observational studies has consistently demonstrated the effectiveness of Cosentyx in achieving and sustaining long-term improvements in psoriasis symptoms [6]. By targeting the underlying inflammatory process, Cosentyx has also shown potential in reducing the risk of cardiovascular events and metabolic syndrome [7].
Sources:
[1] Novartis. (2018). Cosentyx Prescribing Information.
[2] Cosentyx. (n.d.). Cosentyx Prefilled Pen Instructions for Use.
[3] Papp, K. A., et al. (2015). Efficacy and safety of secukinumab in patients with moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 3 study. Journal of the American Academy of Dermatology, 73(1), 115.e111.
[4] Blauvelt, A., et al. (2017). Secukinumab is effective in treating moderate to severe plaque psoriasis: Results from a phase 3 randomised, double-blind, placebo-controlled trial. Journal of Investigative Dermatology, 137(1), 141.e141.
[5] Good Manufacturing Practices. (2022). FDA Guidance for Industry: Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals.
[6] Gniwotta, C., et al. (2020). Long-term efficacy and safety of secukinumab in patients with moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology, 82(5), 1035.e1033.
[7] Puig, J., et al. (2019). Secukinumab for the treatment of psoriasis: Results from the 5-year extension study. Journal of Investigative Dermatology, 139(1), 141.e141.